About: Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia
Creator	Ma, Ronald Tam, Wing Shing, Ka Catalano, Patrick David, H Gibbons, Kristen Lowe, Julia Madsen, Lene Mcintyre, David Sacks, David Tam, Hung
source	Elsevier; Medline; PMC
abstract	Abstract Aims We assessed how altered diagnostic processes and criteria for gestational diabetes mellitus (GDM) recommended by the United Kingdom (UK), Canada and Australia for use during the COVID-19 pandemic would affect both GDM frequency and related adverse outcomes. Methods Secondary analysis of 5974 HAPO study women with singleton pregnancies who underwent 75g OGTTs and HbA1c assays between 24 and 32 weeks’ gestation and who received no treatment for GDM. Results All post COVID-19 modified pathways reduced GDM frequency - UK (81%), Canada (82%) and Australia (25%). Canadian women whose GDM would remain undetected post COVID-19 (missed GDMs) displayed similar rates of pregnancy complications to those with post COVID-19 GDM. Using UK modifications, the missed GDM group were at slightly lower risk whilst the women missed using the Australian modifications were at substantially lower risk. Conclusions The modifications in GDM diagnosis proposed for the UK, Canada and Australia result in differing reductions of GDM frequency. Each has both potential benefits in terms of reduction in potential exposure to COVID-19 and costs in terms of missed opportunities to influence pregnancy and postpartum outcomes. These factors should be considered when deciding which protocol is most appropriate for a particular context.
has issue date	2020-07-30(xsd:dateTime)
bibo:doi	10.1016/j.diabres.2020.108353
bibo:pmid	32739381
has license	els-covid
sha1sum (hex)	2ffd9f0e30321ae89fbfde483bd743810f68082a
schema:url	https://doi.org/10.1016/j.diabres.2020.108353
resource representing a document's title	Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia
has PubMed Central identifier	PMC7391984
has PubMed identifier	32739381
schema:publication	Diabetes Res Clin Pract
resource representing a document's body	covid:2ffd9f0e30321ae89fbfde483bd743810f68082a#body_text
is schema:about of	named entity 'United Kingdom' named entity 'GDM' named entity 'Canada' named entity 'COVID-19' named entity 'adiposity' named entity 'COVID-19' named entity 'c-peptide' named entity 'clinical characteristics' named entity 'OGTT' named entity 'COVID-19' named entity 'GDM' named entity 'OGTT' named entity 'biochemical' named entity 'COVID-19 pandemic' named entity 'alcohol consumption' named entity 'COVID-19 pandemic' named entity 'community transmission' named entity 'risk factor' named entity 'Canada' named entity 'Hong Kong' named entity 'pragmatism' named entity 'obesity' named entity 'COVID-19' named entity 'GDM' named entity 'neonatal' named entity 'mmHg' named entity 'neonatal' named entity 'COVID-19 pandemic' named entity 'neonatal' named entity 'pregnancy' named entity 'weeks of gestation' named entity 'systolic blood pressure' named entity '23.5%' named entity 'first-degree relative' named entity 'pregnancy' named entity 'pregnancy' named entity 'Canada' named entity 'fasting glucose' named entity 'COVID-19' named entity 'GDM' named entity 'OGTT' named entity 'fasting' named entity 'GDM' named entity 'GDM' named entity 'Australia' named entity 'Pathology' named entity 'COVID-19' named entity 'GDM' named entity 'clinical outcomes' named entity 'GDM' named entity 'diagnostic criteria' named entity 'fasting glucose' named entity 'glucose' named entity 'informed consent' named entity 'COVID-19' named entity 'fasting glucose' named entity 'GDM' named entity 'pregnancy' named entity 'GDM' named entity 'physical distancing' named entity 'collection centers' named entity 'Canada' named entity 'glucose' named entity 'birthweight' named entity 'GDM' named entity 'study protocol' named entity 'hypertension' named entity 'United Kingdom' named entity 'Bellflower, California' named entity 'oral glucose tolerance test' named entity 'GDM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software